Anatumomab mafenatox

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]

Anatumomab mafenatox
Monoclonal antibody
TypeFab fragment
SourceMouse
TargetTAG-72
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
  (verify)

It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]

Development was abandoned in 2005.[4]

References

  1. "Active Biotech". activebiotech.com. Retrieved 25 May 2016.
  2. Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson M (2013). "Tumor-Targeted Superantigens". Fusion Protein Technologies for Biopharmaceuticals. pp. 365–381. doi:10.1002/9781118354599.ch24. ISBN 9781118354599.
  3. "Drug info" (PDF). World Health Organization. Retrieved 25 May 2016.
  4. "Anatumomab mafenatox". AdisInsight. Springer Nature Switzerland AG.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.